US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · Renal Impairment · Urinary Tract Infection · SPRO
Spero Therapeutics
Spero Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US HQ
2013 Founded
45 Employees
Public company Type
SPRO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
- Founded
- 2013
- Employees
- 45
- Programs
- 21
- Drugs
- 9
- Patents
- 16
Spero Therapeutics pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Spero Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Spero Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Dipeptidase 1.
- Target
- Dipeptidase 1
- Mechanism
- Renal dipeptidase inhibitor
-
Development asset linked to Spero Therapeutics in public FDA and regional records.
-
imipenem
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Spero Therapeutics's portfolio. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Spero Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Spero Therapeutics in public FDA and regional records.
-
Development asset linked to Spero Therapeutics in public FDA and regional records.